| Bioactivity | LY262691 is a selective CCK-B antagonist with antipsychotic properties. LY262691 decreases the number of spontaneously active A9 and A10 dopamine cells and can be utilized in antipsychotic research[1]. |
| CAS | 138932-35-1 |
| Formula | C22H18BrN3O2 |
| Molar Mass | 436.30 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rasmussen K, et al. Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity. Eur J Pharmacol. 1991 Dec 10;209(1-2):135-8. |
LY262691
CAS: 138932-35-1 F: C22H18BrN3O2 W: 436.30
LY262691 is a selective CCK-B antagonist with antipsychotic properties. LY262691 decreases the number of spontaneously a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.